amantadine has been researched along with valproic acid in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.70) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (39.13) | 29.6817 |
| 2010's | 11 (47.83) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Tegeler, J; Wöller, W | 1 |
| Bauman, AW; Hammond, EJ; Karas, BJ; Wilder, BJ | 1 |
| Alexander, G; Chatterjie, N; Wang, H | 1 |
| Bourgeois, JA; Farrimond, DD; Hilty, DM; Kile, SJ; Sugden, SG | 1 |
| Galgóczy, L; Papp, T; Tóth, L; Vágvölgyi, CS; Virágh, M | 1 |
| Ene-Stroescu, V; Nguyen, T; Waiblinger, BE | 1 |
| Amano, N; Nakamura, T; Ogihara, T; Sasayama, D; Sugiyama, N; Tada, H; Takahashi, Y; Washizuka, S | 1 |
| Chen, J; He, ZF; Rao, Z; Wang, XH; Zhou, CN | 1 |
1 review(s) available for amantadine and valproic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for amantadine and valproic acid
| Article | Year |
|---|---|
Treatment of valproate tremors.
Topics: Amantadine; Cyproheptadine; Diphenhydramine; Humans; Propranolol; Tremor; Valproic Acid | 1983 |
21 other study(ies) available for amantadine and valproic acid
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
[Therapeutic measures in tardive dyskinesia].
Topics: Age Factors; Amantadine; Antipsychotic Agents; Baclofen; Benzodiazepines; Bromocriptine; Deanol; Dihydroxyphenylalanine; Dyskinesia, Drug-Induced; Humans; Phosphatidylcholines; Schizophrenia; Valproic Acid | 1983 |
Synthesis of valproic acid amides of a melatonin derivative, a piracetam and amantadine for biological tests.
Topics: Amantadine; Animals; Melatonin; Pentylenetetrazole; Piracetam; Rodentia; Seizures; Valproic Acid | 2001 |
Pharmacological intervention for cognitive deficits and aggression in frontal lobe injury.
Topics: Adult; Aggression; Amantadine; Cognition Disorders; Conduct Disorder; Donepezil; Frontal Lobe; Humans; Indans; Male; Neurotransmitter Agents; Nootropic Agents; Piperidines; Valproic Acid | 2006 |
In vitro interactions of amantadine hydrochloride, R-(-)-deprenyl hydrochloride and valproic acid sodium salt with antifungal agents against filamentous fungal species causing central nervous system infection.
Topics: Amantadine; Amphotericin B; Antifungal Agents; Central Nervous System Fungal Infections; Drug Interactions; Fungi; Itraconazole; Microbial Sensitivity Tests; Naphthalenes; Selegiline; Terbinafine; Valproic Acid | 2012 |
Successful treatment of catatonia in a young man with schizophrenia and progressive diffuse cerebral atrophy.
Topics: Adolescent; Amantadine; Anticonvulsants; Antiparkinson Agents; Antipsychotic Agents; Atrophy; Catatonia; Cerebral Cortex; Clozapine; Drug Therapy, Combination; Humans; Magnetic Resonance Imaging; Male; Memantine; Schizophrenia; Valproic Acid | 2014 |
A case of severe parkinsonism in an elderly person induced by valproic acid.
Topics: Aged; Amantadine; Anticonvulsants; Brain; Dose-Response Relationship, Drug; Female; Humans; Magnetic Resonance Imaging; Parkinsonian Disorders; Treatment Outcome; Valproic Acid | 2017 |
Disabling tremor induced by long-term use of sodium valproate and lamotrigine: Case report.
Topics: Amantadine; Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Lamotrigine; Male; Middle Aged; Triazines; Trihexyphenidyl; Valproic Acid | 2017 |